A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and the tolerability of siltuximab up to
11.0 mg/kg in combination with bortezomib and dexamethasone for patients with relapsed or
refractory multiple myeloma.